The following presentations will be made during the ESMO (European Society for Medical Oncology) Annual Meeting 2022, which will take place from September 9–13, 2022, in Paris, France, according to an announcement made today by Innate Pharma SA.
1. In a multi-center Phase Ib trial, lacutamab safety and efficacy in patients with KIR3DL2-expressing relapsed/refractory peripheral T-cell lymphoma are being investigated.
- Abstract Number: 647TiP
- Session Type: Trial In Progress Poster
- Session Title: Haematological malignancies
- Session Date: Sunday Sept 11, 2022
- Presenter: Marianna Muller, MD, PharmD, Clinical Development Director at Innate Pharma
2. Oral presentation: ANKET for antigen-specific activation of NK cells in designing multispecific antibodies.
- Session Type: Special session
- Session Title: Next frontiers in drug discoveries
- Date and Time: Monday Sept 12, 2022 9:05 AM – 9:20 AM CEST
- Location: 7.3.U – Urval Auditorium
- Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma
3. Presentation orally: NeoCOAST research platform evaluation of neoadjuvant durvalumab (D) alone or in conjunction with novel medicines in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): Dynamics of circulating tumour DNA (ctDNA) and pharmacodynamic correlations
- Presentation #929MO
- Session Type: Mini Oral Session
- Session Title: Non-metastatic NSCLC and other thoracic malignancies
- Date and Time: Monday Sept 12, 2022 3:15 PM CEST
- Location: 7.3.O – Orléans Auditorium
- Presenter: Jonathan Spicer (Montreal, Canada)
After the presentation, the poster and presentations will be posted in the Publications section of innate-pharma.com.
A first-in-class anti-KIR3DL2 humanised cytotoxicity-inducing antibody called lacutamab (IPH4102) is undergoing clinical trials for the treatment of the rare diseases cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL). Rare T lymphocyte-related cutaneous lymphomas have a dismal prognosis and few effective and secure treatment choices at advanced stages.
Approximately 65% of individuals with all CTCL subtypes express the inhibitory KIR3DL2 receptor, and up to 90% of patients with some aggressive CTCL subtypes, particularly Sézary syndrome. Up to 50% of those with peripheral T-cell lymphoma and mycosis fungoides express it (PTCL). On healthy tissues, it only occasionally expresses itself.
ANKET (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.
Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.
The ongoing development for monalizumab is concentrated on investigating monalizumab in a variety of combination strategies in various malignancies, such as early lung cancer. This includes the Phase 3 PACIFIC-9 study in adults with locally advanced (Stage III), unresectable NSCLC who have not progressed after platinum-based concurrent chemoradiotherapy and the Phase 2 NeoCOAST-2 study in the neoadjuvant early-stage setting of NSCLC.